Meeting Banner
Abstract #3070

A Specific MRI contrast agent for glioma: Targeted Quadruple Mutant IL-13 (TQM-13) conjugated liposomes encapsulated with Magnevist@

Xiaoli Liu1, A. B. Madhankumar2, Patti A. Miller1, Becky Slagle-Webb2, Oliver Mrowczynski2, Akiva Mintz3, Qing X. Yang1, and James R. Connor2

1Radiology, College of Medicine Penn State University, Hershey, PA, United States, 2Neurosurgery, College of Medicine, Penn State University, Hershey, 3Radiology and Nuclear Medicine Wake Forest School of Medicine, NC, USA

There is a clinical need for targeted MRI-contrast agents that are more sensitive and specific in detection of glioma than conventional MRI contrast. We use interleukin-13 (IL-13) as targeting ligand because 75% of glioma cells overexpress IL-13Rα2 significantly1. We investigated the relative efficacy of liposomes conjugated with wild type IL-13 to a variant of IL-13, known as Targeted Quadruple Mutant13 (TQM-13) that has been shown to be more selective for the IL-13Rα2 and binds with higher affinity than the wide type. Our targeted MRI agent, TQM-13-liposomes-Gd, produced specific MRI contrast, delineating tumor, inflamed and normal tissues.

This abstract and the presentation materials are available to members only; a login is required.

Join Here